11/18
09:27 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "hold" rating re-affirmed by analysts at TD Cowen.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "hold" rating re-affirmed by analysts at TD Cowen.
11/15
09:34 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/14
07:35 pm
spro
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/14
04:17 pm
spro
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
Medium
Report
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
11/14
04:05 pm
spro
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Medium
Report
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
11/13
07:46 am
spro
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings [Yahoo! Finance]
11/7
04:05 pm
spro
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
Medium
Report
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
11/4
08:19 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "buy" rating on the stock.
10/29
04:05 pm
spro
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Low
Report
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
10/27
10:23 am
spro
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? [Yahoo! Finance]
Medium
Report
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? [Yahoo! Finance]
10/16
04:05 pm
spro
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Medium
Report
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
10/3
08:18 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
10/2
04:30 pm
spro
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Neutral
Report
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
9/4
04:05 pm
spro
Spero Therapeutics to Present at Upcoming September Investor Conferences
Low
Report
Spero Therapeutics to Present at Upcoming September Investor Conferences